mallax-pic
  • PRESENT

Mallax Pharmaceuticals

Mallax Pharmaceuticals was established in Q4 2020 by Impilo together with Anders Larnholt, an experienced pharma executive, as a pharma company ‘ready-to-use’ with required pharmaceutical processes and licenses

Impilo’s ambition is to invest significant capital and resources in building a platform of established pharmaceuticals and OTC products for customers and patients across Europe – with a wide size range for any individual deal between EUR 10m and EUR 300m.

Responsible Partner:

Magnus Edlund

Impilo Board Members:

Magnus Edlund

Victor Steien

Industry:

Pharmaceuticals / OTC

CEO:

Anders Larnholt

Acquisition date:

December 2020

Homepage:

http://www.mallaxpharma.com/

Holländargatan 20
SE-111 60 Stockholm
Sweden
info@impilo.se
+46 8 401 00 60

Kongens Nytorv 28
1050 Copenhagen
Denmark
info@impilo.se
+46 8 401 00 60

Linkedin-in

Impilo is a healthcare-focused investment company with the ambition to provide know-how, a proactive approach to drive positive change, capital and new perspectives to its portfolio companies. This will yield strong returns to Impilo’s investors.